[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366026-105":59,"doc-detail-366026-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mir-145-encapsulated-small-extracellular-vesicles-inhibit-colorectal-cancer-progression-downregulating-fascin-actin-bundling-protein-1-expression","MiR-145 encapsulated small extracellular vesicles inhibit colorectal cancer progression - downregulating fascin actin-bundling protein 1 expression","","Drug degradation limits effective gene therapies for cancers. This study develops a bioactive nanosized composite using human umbilical cord mesenchymal stem cell–derived small extracellular vesicles (hucMSC sEVs) to deliver the tumor suppressor miR-145 together with erbium-doped rare earth nanoparticles for enhanced in vivo delivery and near-infrared (NIR) II fluorescence tracking. In an axenografted murine CRC model, miR-145-loaded sEVs suppress tumor progression by downregulating FSCN1 expression, with favorable biosafety and strong tumor-site accumulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mir-145-encapsulated-small-extracellular-vesicles-inhibit-colorectal-cancer-progression-downregulating-fascin-actin-bundling-protein-1-expression/366026/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mir-145-encapsulated-small-extracellular-vesicles-inhibit-colorectal-cancer-progression-downregulating-fascin-actin-bundling-protein-1-expression/366026.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does the study enhance delivery and tracking of miR-145 for colorectal cancer treatment?","Question",{"text":112,"@type":113},"It uses hucMSC-derived small extracellular vesicles loaded with miR-145, combined with erbium-doped rare earth nanoparticles. This design improves in vivo delivery and enables near-infrared (NIR) II fluorescence tracking of nucleic acid drugs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What loading and functional effects are reported for miR-145-encapsulated sEVs?",{"text":117,"@type":113},"Efficient miR-145 loading is achieved via a dynamic combination of sonication and electroporation. The resulting miR-145-encapsulated sEVs inhibit tumor growth by downregulating FSCN1 expression in vitro and in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"Where do miRNA@sEVs accumulate after administration and what is their in vivo behavior?",{"text":121,"@type":113},"Fluorescent signals predominantly localize in the mouse liver and spleen, with substantial accumulation in tumors. Tumor-site fluorescence peaks at about 8 hours after intravenous injection, and circulation half-time is measured at about 4 hours.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366026,1790265671,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Chen et al. Stem Cell Research & Therapy (2025) 16:343 [https://doi.org/10.1186/s13287-025-04456-6](https://doi.org/10.1186/s13287-025-04456-6)  \nStem Cell Research & Therapy  \nRESEARCH Open Access  \nMiR-145 encapsulated small extracellular  vesicles inhibit colorectal cancer progression by downregulating fascin actin-bundling protein 1 expression  \nYanxia Chen 1,2,6, Meijuan He3, Lei Cui4, Jianguo Zhang 1, Hanpeng Huang3* and Zhimin Tao 1,2,5*  \nAbstract  \nBackground Drug degradation poses a significant challenge in the pursuit of effective gene therapies for cancers. Methods Here we have developed a bioactive nanosized composite that utilizes human umbilical cord mesenchymal stem cells (hucMSCs) derived small extracellular vesicles (sEVs), to carry tumor suppressor miR-145 alongside erbium-doped rare earth nanoparticles (ErNPs) . This approach not only enhances in vivo delivery but also facilitates real-time fluorescence tracking of nucleic acid drugs in the near infrared (NIR) II window. With this technique, we are able to realize and visualize the effective inhibition of colorectal cancer (CRC) progression in axenografted murine model.  \nResults Our results revealed that the efficient loading of miR-145 into sEVs could be achieved through a dynamic combination of sonication and electroporation. The resulting miR-145-encapsulated sEVs (i. e., miRNA@sEVs) exhibited a profound ability to hinder tumor growth by effectively downregulating the expression offascin actin-bundling protein 1 (FSCN1), both in vitro and in vivo. Additionally, the circulation half-time of miRNA@sEVs was measured tobe ~ 4 h and the fluorescence at the tumor sites reached a peak intensity at ~ 8 h after intravenous injection of sEVs particles. Finally, the fluorescent signals of miRNA@sEVs were predominantly localized in the mouse liver and spleen, with substantial accumulation in tumors.  \nConclusions Our results illuminated the excellent biosafety of miRNA@sEVs and their high accumulation in tumors, leading to efficient suppression of tumor progression. This research heralds a promising advancement in gene therapy, paving the way for more effective and safer treatment options.  \nClinical trial number Not applicable.  \nKeywords Small extracellular vesicles, MicroRNA, Colorectal cancer, Fascin actin-bundling protein 1, Near-infrared II fluorescence  \n*Correspondence: Hanpeng Huang [hhp405@163.com](hhp405@163.com)[ ](hhp405@163.com)Zhimin Tao [jsutao@ujs.edu.cn](jsutao@ujs.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nChen et al. Stem Cell Research & Therapy (2025) 16:343  \nIntroduction  \nColorectal cancer (CRC) is one of the most prevalent malignancies worldwide. While its incidence typically rises with age, an alarming trend shows that younger adults are increasingly at risk as well [1]. In the United States, CRC tragically remains the second leading caus","cbCaigLUBp1cCcT4","https://ap.wps.com/l/cbCaigLUBp1cCcT4","pdf",4237671,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Colorectal cancer overview\n## MicroRNA and miR-145 in CRC","[{\"question\":\"How does the study enhance delivery and tracking of miR-145 for colorectal cancer treatment?\",\"answer\":\"It uses hucMSC-derived small extracellular vesicles loaded with miR-145, combined with erbium-doped rare earth nanoparticles. This design improves in vivo delivery and enables near-infrared (NIR) II fluorescence tracking of nucleic acid drugs.\"},{\"question\":\"What loading and functional effects are reported for miR-145-encapsulated sEVs?\",\"answer\":\"Efficient miR-145 loading is achieved via a dynamic combination of sonication and electroporation. The resulting miR-145-encapsulated sEVs inhibit tumor growth by downregulating FSCN1 expression in vitro and in vivo.\"},{\"question\":\"Where do miRNA@sEVs accumulate after administration and what is their in vivo behavior?\",\"answer\":\"Fluorescent signals predominantly localize in the mouse liver and spleen, with substantial accumulation in tumors. Tumor-site fluorescence peaks at about 8 hours after intravenous injection, and circulation half-time is measured at about 4 hours.\"}]","MiR-145 encapsulated small extracellular vesicles inhibit colorectal cancer progression - downregulating fascin actin-bundling protein 1 expression | PDF",1790163597,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b545dee208a74221b71fee43ba1f1894.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11977c8b1741749f7ad96d0f537b2eed.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a282c811cddb759f78b0eb19e7ff59c0.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43b02f62ccb340f5b0d2bc85121a272f.webp",980,1306]